整合临床基因组分析揭示当前吸烟者脑膜瘤中异源代谢基因下调
该研究分析88例脑膜瘤样本,按吸烟状态分组,采用全外显子测序和RNA测序。当前吸烟者脑膜瘤NOTCH2突变率高于既往和从不吸烟者,AKT1突变在吸烟者中缺失,且异源代谢基因UGT2A1和UGT2A2显著下调,伴细胞分裂相关基因集富集。
要点
- 当前吸烟者脑膜瘤NOTCH2突变率高于既往和从不吸烟者(p<0.05)。
- 当前或既往吸烟者脑膜瘤中未见AKT1突变,与非吸烟者相比p=0.046。
- 当前吸烟者UGT2A1和UGT2A2表达显著低于既往和从不吸烟者。
核心结论
- 当前吸烟者脑膜瘤更可能携带NOTCH2突变,且AKT1突变在当前或既往吸烟者中缺失。
- 当前和既往吸烟者均显示与DNA错配修复相关的突变特征。
- 当前吸烟者脑膜瘤中异源代谢酶UGT2A1和UGT2A2下调,并富集细胞分裂和DNA复制控制相关基因集。
研究设计与样本
- 研究分析了88例脑膜瘤肿瘤样本,采用全外显子测序评估体细胞突变负荷,RNA测序数据用于识别差异表达基因和基因集富集分析。
- 57例患者无吸烟史,22例为既往吸烟者,9例为当前吸烟者。
主要发现
- 临床数据显示不同吸烟状态间自然病史无主要差异。
- 当前或既往吸烟者AKT1突变率缺失,与非吸烟者相比p=0.046;当前吸烟者NOTCH2突变率高于既往和从不吸烟者(p<0.05)。
- 当前和既往吸烟者的突变特征显示DNA错配修复 disrupted(余弦相似度=0.759和0.783)。
- 当前吸烟者 vs 既往吸烟者:UGT2A1 Log2FC=-3.97,padj=0.0347;UGT2A2 Log2FC=-4.18,padj=0.0304;当前吸烟者 vs 从不吸烟者:UGT2A1 Log2FC=-3.86,padj=0.0235;UGT2A2 Log2FC=-4.20,padj=0.0149。
- 当前吸烟者GSEA显示异源代谢下调,富集G2M检查点、E2F靶点和有丝分裂纺锤体(FDR<25% each)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Meningiomas are the most common primary intracranial tumor. Recently, various genetic classification systems for meningioma have been described. We sought to identify clinical drivers of different molecular changes in meningioma. As such, clinical and genomic consequences of smoking in patients with meningiomas remain unexplored. METHODS: 88 tumor samples were analyzed in this study. Whole exome sequencing (WES) was used to assess somatic mutation burden. RNA sequencing data was used to identify differentially expressed genes (DEG) and genes sets (GSEA). RESULTS: Fifty-seven patients had no history of smoking, twenty-two were past smokers, and nine were current smokers. The clinical data showed no major differences in natural history across smoking status. WES revealed absence of AKT1 mutation rate in current or past smokers compared to non-smokers (p = 0.046). Current smokers had increased mutation rate in NOTCH2 compared to past and never smokers (p < 0.05). Mutational signature from current and past smokers showed disrupted DNA mismatch repair (cosine-similarity = 0.759 and 0.783). DEG analysis revealed the xenobiotic metabolic genes UGT2A1 and UGT2A2 were both significantly downregulated in current smokers compared to past (Log2FC = - 3.97, padj = 0.0347 and Log2FC = - 4.18, padj = 0.0304) and never smokers (Log2FC = - 3.86, padj = 0.0235 and Log2FC = - 4.20, padj = 0.0149). GSEA analysis of current smokers showed downregulation of xenobiotic metabolism and enrichment for G2M checkpoint, E2F targets, and mitotic spindle compared to past and never smokers (FDR < 25% each). CONCLUSION: In this study, we conducted a comparative analysis of meningioma patients based on their smoking history, examining both their clinical trajectories and molecular changes. Meningiomas from current smokers were more likely to harbor NOTCH2 mutations, and AKT1 mutations were absent in current or past smokers. Moreover, both current and past smokers exhibited a mutational signature associated with DNA mismatch repair. Meningiomas from current smokers demonstrate downregulation of xenobiotic metabolic enzymes UGT2A1 and UGT2A2, which are downregulated in other smoking related cancers. Furthermore, current smokers exhibited downregulation xenobiotic metabolic gene sets, as well as enrichment in gene sets related to mitotic spindle, E2F targets, and G2M checkpoint, which are hallmark pathways involved in cell division and DNA replication control. In aggregate, our results demonstrate novel alterations in meningioma molecular biology in response to systemic carcinogens.
引用
- Khan AB, Patel R, McDonald MF, et al. Integrated clinical genomic analysis reveals xenobiotic metabolic genes are downregulated in meningiomas of current smokers. J Neurooncol. 2023. PMID: 37318677. doi:10.1007/s11060-023-04359-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。